Alma Luisa Revilla Vazquez

Alma Luisa Revilla Vazquez

Auto-generated profile, based on publicly available information

Alma Luisa Revilla Vazquez

Masaryk University, Faculty of Science, Department of Analytical Chemistry, Brno, Czech Republic

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2007 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
MCM. Candelaria
M. Candelaria
DGD. Gallardo-Rincón
D. Gallardo-Rincón
CAC. Arce
C. Arce
LCL. Cetina
L. Cetina
JAJ.L. Aguilar-Ponce
J.L. Aguilar-Ponce
ADAlfonso Dueñas-González
Alfonso Dueñas-González
Background: Epigenetic aberrations lead to chemotherapy resistance; hence, their reversal by inhibitors of DNA methylation and histone deacetylases may overcome it. Patients and methods: Phase II, single-arm study of hydralazine and magnesium valproate added to the same schedule of chemotherapy on which patients were progressing. Schedules comprised cisplatin, carboplatin, paclitaxel, vinorelbine, gemcitabine, pemetrexed, topotecan, doxorubicin, cyclophosphamide, and anastrozole. Patients received hydralazine at 182 mg for rapid, or 83 mg for slow, acetylators, and magnesium valproate at 40 mg/kg, beginning a week before chemotherapy. Response, toxicity, DNA methylation, histone deacetylase activity, plasma valproic acid, and hydralazine levels were evaluated. Results: Seventeen patients were evaluable for toxicity and 15 for response. Primary sites included cervix (3), breast (3), lung (1), testis (1), and ovarian (7) carcinomas. A clinical benefit was observed in 12 (80%) patients: four PR, and eight SD. The most significant toxicity was hematologic. Reduction in global DNA methylation, histone deacetylase activity, and promoter demethylation were observed. Conclusions: The clinical benefit noted with the epigenetic agents hydralazine and valproate in this selected patient population progressing to chemotherapy’ and re-challenged with the same chemotherapy schedule after initiating hydralazine and valproate’ lends support to the epigenetic-driven tumor-cell chemoresistance hypothesis (ClinicalTrials.gov Identifier: NCT00404508).

29 April 2005 in BMC Cancer
Verified
Journal Article
Open access
PDF file
PZPilar Zambrano
Pilar Zambrano
BSBlanca Segura-Pacheco
Blanca Segura-Pacheco
EPEnrique Perez-Cardenas
Enrique Perez-Cardenas
LCLucely Cetina
Lucely Cetina
ARAlma Revilla-Vazquez
Alma Revilla-Vazquez
ADAlfonso Dueñas-González
Alfonso Dueñas-González
Background: The antihypertensive compound hydralazine is a known demethylating agent. This phase I study evaluated the tolerability and its effects upon DNA methylation and gene reactivation in patients with untreated cervical cancer. Methods: Hydralazine was administered to cohorts of 4 patients at the following dose levels: I) 50 mg/day, II) 75 mg/day, III) 100 mg/day and IV) 150 mg/day. Tumor biopsies and peripheral blood samples were taken the day before and after treatment. The genes APC, MGMT; ER, GSTP1, DAPK, RARβ, FHIT and p16 were evaluated pre and post-treatment for DNA promoter methylation and gene expression by MSP (Methylation-Specific PCR) and RT-PCR respectively in each of the tumor samples. Methylation of the imprinted H19 gene and the "normally methylated" sequence clone 1.2 was also analyzed. Global DNA methylation was analyzed by capillary electrophoresis and cytosine extension assay. Toxicity was evaluated using the NCI Common Toxicity Criteria. Results: Hydralazine was well tolerated. Toxicities were mild being the most common nausea, dizziness, fatigue, headache and palpitations. Overall, 70% of the pretreatment samples and all the patients had at least one methylated gene. Rates of demethylation at the different dose levels were as follows: 50 mg/day, 40%; 75 mg/day, 52%, 100 mg/day, 43%, and 150 mg/day, 32%. Gene expression analysis showed only 12 informative cases, of these 9 (75%) re-expressed the gene. There was neither change in the methylation status of H19 and clone 1.2 nor changes in global DNA methylation. Conclusion: Hydralazine at doses between 50 and 150 mg/day is well tolerated and effective to demethylate and reactivate the expression of tumor suppressor genes without affecting global DNA methylation

20 December 2006 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CAClaudia Arce
Claudia Arce
Carlos Pérez-PlasenciaCarlos Pérez-Plasencia
Carlos Pérez-Plasencia
AGAurora González-Fierro
Aurora González-Fierro
ECErick De La Cruz-Hernández
Erick De La Cruz-Hernández
ARAlma Revilla-Vázquez
Alma Revilla-Vázquez
ADAlfonso Dueñas-González
Alfonso Dueñas-González
Aberrant DNA methylation and histone deacetylation participate in cancer development and progression; hence, their reversal by inhibitors of DNA methylation and histone deacetylases (HDACs) is at present undergoing clinical testing in cancer therapy. As epigenetic alterations are common to breast cancer, in this proof-of-concept study demethylating hydralazine, plus the HDAC inhibitor magnesium valproate, were added to neoadjuvant doxorubicin and cyclophosphamide in locally advanced breast cancer to assess their safety and biological efficacy. This was a single-arm interventional trial on breast cancer patients (ClinicalTrials.gov Identifier: NCT00395655). After signing informed consent, patients were typed for acetylator phenotype and then treated with hydralazine at 182 mg for rapid-, or 83 mg for slow-acetylators, and magnesium valproate at 30 mg/kg, starting from day –7 until chemotherapy ended, the latter consisting of four cycles of doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 every 21 days. Core-needle biopsies were taken from primary breast tumors at diagnosis and at day 8 of treatment with hydralazine and valproate. 16 patients were included and received treatment as planned. All were evaluated for clinical response and toxicity and 15 for pathological response. Treatment was well-tolerated. The most common toxicity was drowsiness grades 1–2. Five (31%) patients had clinical CR and eight (50%) PR for an ORR of 81%. No patient progressed. One of 15 operated patients (6.6%) had pathological CR and 70% had residual disease <3 cm. There was a statistically significant decrease in global 5mC content and HDAC activity. Hydralazine and magnesium valproate up- and down-regulated at least 3-fold, 1,091 and 89 genes, respectively. Hydralazine and magnesium valproate produce DNA demethylation, HDAC inhibition, and gene reactivation in primary tumors. Doxorubicin and cyclophosphamide treatment is safe, well-tolerated, and appears to increase the efficacy of chemotherapy. A randomized phase III study is ongoing to support the efficacy of so-called epigenetic or transcriptional cancer therapy.

1 July 2011 in The Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
JCJose Juan Escobar Chavez
Jose Juan Escobar Chavez
DBDalia Bonilla-Martínez
Dalia Bonilla-Martínez
MVMartha Angélica Villegas-González
Martha Angélica Villegas-González
EMEva Molina-Trinidad
Eva Molina-Trinidad
NCNorma Casas-Alancaster
Norma Casas-Alancaster
ARAlma Luisa Revilla-Vázquez
Alma Luisa Revilla-Vázquez

1 November 2009 in The Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
JCJose Juan Escobar Chavez
Jose Juan Escobar Chavez
DBDalia Bonilla‐Martínez
Dalia Bonilla‐Martínez
MVMartha Angélica Villegas‐González
Martha Angélica Villegas‐González
ARAlma Luisa Revilla‐Vázquez
Alma Luisa Revilla‐Vázquez

1 June 2006 in Journal of Translational Medicine
Verified
Journal Article
Open access
BSBlanca Segura-Pacheco
Blanca Segura-Pacheco
EPEnrique Perez-Cardenas
Enrique Perez-Cardenas
LTLUCIA TAJA-CHAYEB
LUCIA TAJA-CHAYEB
ABALMA DELIA CHAVEZ BLANCO
ALMA DELIA CHAVEZ BLANCO
ARAlma Revilla-Vazquez
Alma Revilla-Vazquez
ADAlfonso Dueñas-González
Alfonso Dueñas-González
Background: The development of resistance to cytotoxic chemotherapy continues to be a major obstacle for successful anticancer therapy. It has been shown that cells exposed to toxic concentrations of commonly used cancer chemotherapy agents develop DNA hypermetylation. Hence, demethylating agents could play a role in overcoming drug resistance. Methods: MCF-7 cells were rendered adriamycin-resistant by weekly treatment with adriamycin. Wild-type and the resulting MCF-7/Adr cells were analyzed for global DNA methylation. DNA methyltransferase activity and DNA methyltransferase (dnmt) gene expression were also determined. MCF-7/Adr cells were then subjected to antisense targeting of dnmt1, -3a, and -b genes and to treatment with the DNA methylation inhibitor hydralazine to investigate whether DNA demethylation restores sensitivity to adriamycin. Results: MCF-7/Adr cells exhibited the multi-drug resistant phenotype as demonstrated by adriamycin resistance, mdr1 gene over-expression, decreased intracellular accumulation of adriamycin, and cross-resistance to paclitaxel. The mdr phenotype was accompanied by global DNA hypermetylation, over-expression of dnmt genes, and increased DNA methyltransferase activity as compared with wild-type MCF-7 cells. DNA demethylation through antisense targeting of dnmts or hydralazine restored adriamycin sensitivity of MCF-7/Adr cells to a greater extent than verapamil, a known inhibitor of mdr protein, suggesting that DNA demethylation interferes with the epigenetic reprogramming that participates in the drug-resistant phenotype. Conclusion: We provide evidence that DNA hypermethylation is at least partly responsible for development of the multidrug-resistant phenotype in the MCF-7/Adr model and that hydralazine, a known DNA demethylating agent, can revert the resistant phenotype.